Zoledronic acid

Details

Files

Generic Name:

Zoledronic acid

Project Status:

Complete

Therapeutic Area:

Osteoporosis, postmenopausal women

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Brand Name:

Aclasta

Project Line:

Reimbursement Review

Project Number:

SR0114-000

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Osteoporosis, postmenopausal women

Recommendation Type:

Do not list

Final Recommendation:

June 25, 2008

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Last Updated : November 29, 2007